NEWARK, Calif., May 9, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two upcoming investor conferences:
Bank of America Merrill Lynch Healthcare Conference in Las Vegas Nevada on Thursday May 15 at 11:00 am Eastern Time (8:00 am Pacific Time).
UBS Global Healthcare Conference in New York City on Monday May 19 at 9:00 am Eastern Time (6:00 am Pacific Time).
The presentations will be webcast, and the webcasts can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of each webcast will be archived for 30 days on the company's website.
Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.
CONTACT: August J. Moretti
Depomed, Inc. 510.744.8000